News Related to Brigatinib

Related coverage linked through entity extraction aliases.

Lung Cancer Drug Brigatinib Shows Promise in Enhancing Ovarian Cancer Treatment

Mar 17, 2026

Mayo Clinic researchers found that Brigatinib, an FDA-approved lung cancer drug, can block survival pathways in ovarian cancer cells when combined with PARP inhibitors, potentially overcoming treatment resistance.

New Cancer Research Shows Promise in Blood Cancer, Prostate Cancer, and Ovarian Cancer Treatment

Mar 17, 2026

Recent studies demonstrate high response rates for antibody-drug conjugate in rare blood cancer, improved outcomes with metastasis-directed radiation in prostate cancer, and a novel drug combination strategy for ovarian cancer resistance.